UBS Group’s ResMed RMD Stock Holding History

UBS Group’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,000	Closed	-$1.93M	–	11063
2025 Q4	$1.93M	Sell	8,000 -16,000	-67%	-$4.09M	﹤0.01%	5011
2025 Q3	$6.57M	Buy	24,000 +16,200	+208%	+$4.43M	﹤0.01%	3755
2025 Q2	$2.01M	Sell	7,800 -24,750	-76%	-$5.9M	﹤0.01%	4811
2025 Q1	$7.29M	Buy	32,550 +24,600	+309%	+$5.74M	﹤0.01%	3390
2024 Q4	$1.82M	Sell	7,950 -250	-3%	-$60.2K	﹤0.01%	4813
2024 Q3	$2M	Buy	8,200 +5,900	+257%	+$1.32M	﹤0.01%	3994
2024 Q2	$440K	Sell	2,300 -30,755	-93%	-$6.24M	﹤0.01%	5095
2024 Q1	$6.55M	Buy	33,055 +11,805	+56%	+$2.16M	﹤0.01%	2681
2023 Q4	$3.66M	Buy	+21,250	New	+$3.26M	﹤0.01%	3115
2023 Q3	–	Sell	-13,665	Closed	-$2.99M	–	9882
2023 Q2	$2.99M	Buy	13,665 +9,265	+211%	+$2.06M	﹤0.01%	3112
2023 Q1	$964K	Sell	4,400 -22,501	-84%	-$4.88M	﹤0.01%	4134
2022 Q4	$5.6M	Buy	26,901 +19,401	+259%	+$4.26M	﹤0.01%	2392
2022 Q3	$1.64M	Buy	+7,500	New	+$1.71M	﹤0.01%	3327
2022 Q1	–	Sell	-8,900	Closed	-$2.32M	–	10803
2021 Q4	$2.32M	Sell	8,900 -3,500	-28%	-$908K	﹤0.01%	3596
2021 Q3	$3.27M	Buy	12,400 +2,900	+31%	+$793K	﹤0.01%	3129
2021 Q2	$2.34M	Buy	+9,500	New	+$2M	﹤0.01%	3436
2020 Q4	–	Sell	-19,400	Closed	-$3.33M	–	8689
2020 Q3	$3.33M	Buy	+19,400	New	+$3.58M	﹤0.01%	2574
2020 Q2	–	Sell	-11,000	Closed	-$1.62M	–	8289
2020 Q1	$1.62M	Sell	11,000 -7,750	-41%	-$1.23M	﹤0.01%	2942
2019 Q4	$2.91M	Sell	18,750 -1,750	-9%	-$252K	﹤0.01%	3169
2019 Q3	$2.77M	Sell	20,500 -1,500	-7%	-$197K	﹤0.01%	2976
2019 Q2	$2.69M	Sell	22,000 -2,000	-8%	-$222K	﹤0.01%	2884
2019 Q1	$2.5M	Sell	24,000 -79,000	-77%	-$8.15M	﹤0.01%	2806
2018 Q4	$11.7M	Sell	103,000 -12,000	-10%	-$1.29M	0.01%	1452
2018 Q3	$13.3M	Buy	115,000 +102,500	+820%	+$11.2M	0.01%	1536
2018 Q2	$1.29M	Sell	12,500 -33,108	-73%	-$3.35M	﹤0.01%	3556
2018 Q1	$4.49M	Sell	45,608 -1,392	-3%	-$132K	﹤0.01%	2412
2017 Q4	$3.98M	Sell	47,000 -11,700	-20%	-$967K	﹤0.01%	2573
2017 Q3	$4.52M	Buy	58,700 +31,740	+118%	+$2.43M	﹤0.01%	2305
2017 Q2	$2.1M	Sell	26,960 -8,222	-23%	-$588K	﹤0.01%	2969
2017 Q1	$2.53M	Sell	35,182 -98,888	-74%	-$6.83M	﹤0.01%	2722
2016 Q4	$8.32M	Buy	134,070 +61,550	+85%	+$3.77M	﹤0.01%	1669
2016 Q3	$4.7M	Sell	72,520 -78,261	-52%	-$5.21M	﹤0.01%	2078
2016 Q2	$9.53M	Buy	+150,781	New	+$8.89M	0.01%	1414
2016 Q1	–	Sell	-61,310	Closed	-$3.29M	–	8077
2015 Q4	$3.29M	Sell	61,310 -210,715	-77%	-$11.9M	﹤0.01%	2332
2015 Q3	$13.9M	Buy	272,025 +151,335	+125%	+$8.15M	0.01%	1136
2015 Q2	$6.8M	Buy	120,690 +116,050	+2,501%	+$7.32M	﹤0.01%	1796
2015 Q1	$333K	Sell	4,640 -25,200	-84%	-$1.64M	﹤0.01%	4469
2014 Q4	$1.67M	Buy	+29,840	New	+$1.56M	﹤0.01%	3069

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group's RMD Position: Q1 2026 in Review

UBS Group reduced its ResMed (RMD) stake by 20% in Q1 2026, selling an estimated $44.8M and leaving 726,811 shares worth $163M. The position accounts for 0.02% of the portfolio, ranked #721.

UBS Group first reported a position in RMD in Q4 2014 and has held it in 46 quarters since. The position peaked at $239M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

UBS Group held 726,811 shares of ResMed worth $163M as of Q1 2026.
UBS Group sold 179,604 ResMed shares in Q1 2026, an estimated $44.8M.
ResMed made up 0.02% of UBS Group's portfolio in Q1 2026, its #721 holding.
UBS Group first reported a position in ResMed in Q4 2014 and has held it in 46 quarters since.
UBS Group's ResMed position peaked at $239M in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.